Table 1 Recipient and donor demographics of the IPF treatment group and historical control group

ID

Recipient Gender (M/F)

Recipient Age (Years)

Anti-fibrotic Drug

Cardio-Pulmonary Rehabilitation

Time on Therapy (Days)

FVC at start (%pred)

TLC at start (%pred)

DL_CO at start (%pred)

6MWT at start (m)

Time on WL (Days)

LAS at listing

Type of LTx (S/SS)

Donor Gender (M/F)

Donor Age (Years)

Type of Donor

CMV Donor/Recipient

1

F

62

PFD

no

735

91

72

46

529

762

32

SS

F

17

DBD

D+/R+

2

M

61

PFD

CPR

545

71

61

37

379

179

31

SS

F

67

DCD cat III

D-/R-

3

M

51

PFD

CPR

387

88

80

47

552

29

35

SS

M

37

DBD

D+/R-

4

M

63

PFD

CPR

539

52

45

32

384

51

30

SS

M

55

DBD

D-/R+

5

M

55

PFD

CPR

188

56

52

35

631

25

29

SS

M

23

DBD

D+/R-

6

M

64

PFD

no

115

62

48

39

503

163

33

SS

M

35

DCD cat V

D+/R+

7

M

64

PFD

no

65

79

56

28

267

419

37

S

F

42

DBD

D+/R-

8

M

65

NIN

no

1003

80

69

58

598

155

31

SS

M

62

DBD

D+/R-

9

M

56

NIN

no

194

58

56

29

275

74

32

SS

M

39

DCD cat III

D-/R-

Mean or Median

60.1 ± 4.9

419 ± 315

70.8 ± 14.5

59.9 ± 11.7

39.0 ± 9.8

457.6 ± 135.6

155 (40–299)

32.2 ± 2.5

43.6 ± 17.1

1

M

57

/

no

/

/

/

/

/

279

33

SS

F

48

DCD cat III

D-/R+

2

M

62

/

no

/

/

/

/

/

153

35

SS

F

66

DBD

D+/R+

3

M

55

/

no

/

/

/

/

/

17

34

SS

M

74

DBD

D+/R+

4

M

59

/

CPR

/

/

/

/

/

274

32

SS

M

22

DCD cat III

D-/R+

5

M

59

/

CPR

/

/

/

/

/

253

29

SS

M

57

DBD

D-/R-

6

M

65

/

CPR

/

/

/

/

/

112

26

S

M

37

DBD

D+/R+

Mean or Median

59.5 ± 3.6^a

203 (88–275)^a

31.5 ± 3.4^a

50.7 ± 19.^a

ID

Ischemic Time 1^th/2^nd Lung (min)

Immuno-suppressive Regimen

Time to Extubation (Hours)

PGD at 72 h

Time on ICU (Days)

Time in Hospital (Days)

AR or LB Episodes (Number)

Most Severe AR or LB (Grade)

Respiratory infection before Discharge (Presence = 1)

Respiratory Pathogen before Discharge

1

187/320

rATG/FK/MMF/CS

34

0

6

16

0

0

0

/

2

432/580

rATG/FK/MMF/CS

20

3

7

20

1

1

1

E. coli, S. viridans

3

498/694

No ATG, FK/MMF/CS

37

0

4

16

2

2

1

A. baumanii, E. coli, S. aureus

4

417/631

rATG/FK/MMF/CS

65

1

13

26

1

1

0

/

5

366/515

rATG/FK/MMF/CS

41

2

6

17

0

0

1

C. freundii

6

385/582

rATG/FK/MMF/CS

37

1

4

16

3

2

0

/

7

341

rATG/CsA/AZA/CS

33

2

3

21

0

0

1

H. influenza, MRSA

8

180/356

rATG/FK/MMF/CS

178

3

10

28

1

3

1

H. influenza, S. pneumoniae

9

239/356

rATG/FK/MMF/CS

38

2

5

23

1

2

0

/

338 ± 113/504 ± 142

37 (33.5–53)

2 (0.5–2.5)

6.4 ± 3.2

20.3 ± 4.6

1 (0–1.5)

1 (0–2)

1

404/626

rATG/FK/MMF/CS

72

0

7

19

1

2

0

/

2

220/412

rATG/FK/MMF/CS

16

1

7

25

2

3

1

S. aureus

3

288/431

rATG/FK/MMF/CS

432

3

60

253

1

1

1

P. aeruginosa, K. pneumoniae,

4

276/423

rATG/FK/MMF/CS

48

2

15

32

1

1

1

E. faecalis

5

209/439

rATG/CsA/AZA/CS

48

2

23

32

0

0

1

K. oxytoca

6

186

rATG/CsA/AZA/CS

24

1

8

20

2

1

0

/

264 ± 79^a/466 ± 90^a

48 (22–162)^a

1.5 (0.8–2.3)^a

20.0 ± 20.6^b

63.5 ± 93^a

1 (0.75–2.0)^a

1 (0.75–2.25)^a

ID

Time of Follow-up(Months)

Status (Dead = 1)

Last FVC Post-LTx (%pred)

Last FEV₁ Post-LTx (%pred)

1

7.7

0

145

147

2

8.6

0

106

90

3

16.9

0

70

68

4

21.9

0

90

67

5

25.8

0

93

93

6

27.1

0

123

126

7

19.8

1

110

107

8

13.8

0

119

115

9

56.3

0

132

141

19.8 (11.2–26.5)

109 ± 23.1

106 ± 29.1

1

14.9

0

117

76

2

23.5

0

104

99

3

37.0

0

67

61

4

38.6

0

107

92

5

52.4

0

104

58

6

12.2

1

79

82

30.3 (14.2–42.1)

96.3 ± 19.1

78.0 ± 16.4